Pyxis Oncology BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

Pyxis Advisory Group, a diversified advisory firm headquartered in Texas and serves the global industrial sector, is excited to announce the launch of its European entity, Pyxis Advisory Group AG ...

A huge range of new products includes a digital film camera with a 12K RGBW sensor, a powerful ATEM 4 M/E switcher and an ST 2110 standards converter. Blackmagic Design is showcasing a large range of ...

Blackmagic PYXIS 12K will be available in July from Blackmagic Design resellers worldwide for US$4,995. The Blackmagic PYXIS 12K will be demonstrated on the Blackmagic Design NAB 2025 booth #SL216.

With huge banners announcing it already plastered all over the LVCC, the PYXIS 12K is not exactly one of NAB 2025's surprises, but the official unveil is all about a rather interesting new camera at a ...

Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – William Blair issued their FY2027 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, March 18th.

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20% ...

Built for professional use, the Blackmagic Pyxis takes the proven HDR full-frame sensor from the Blackmagic Cinema Camera 6K and puts it in a box-style camera that can be configured to suit ...

Constellation announced plans to buy Calpine Corp. in a nearly $30 billion transaction this morning. Constellation says the deal will make it America's biggest electric utility, and grow earnings ...

Shares of Pyxis Oncology (NASDAQ:PYXS) cratered 46% Thursday, the day after the company reported preliminary results from a Phase 1 study for its lead oncology drug candidate, PYX-201, prompting a ...

Pyxis Oncology had cash and cash equivalents, including restricted cash and short-term investments of $157.2 million. Pyxis says that its current cash, cash equivalents, and short-term investments ...